Pharma Focus Asia

Cidara Therapeutics and Wuxi XDC Expand Collaboration for IND-Enabling CMC Development

Thursday, February 02, 2023

Cidara Therapeutics announced an expansion of their existing collaboration under which Wuxi XDC will provide investigational new drug (ind)-enabling chemistry, manufacturing and controls (CMC) development services for cidara’s CD73 oncology DFC programme.

The expansion of this relationship by combining WuXi XDC’s core competencies in bioconjugates manufacturing with the expertise in DFCs will advance the manufacturing of first-in-class CD73 oncology DFC.

This expanded partnership builds a strong testament to the industry-leading capabilities and expertise. The commitment to build an innovation ecosystem for bioconjugates by offering global open-access technology platforms with premier quality standards will support the partners worldwide to build innovative ideas into transformative new treatments for patients.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024